Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan Frett

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Expert Opinion on Therapeutic Patents|October 5, 2022
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present)Baku Acharya, Brendan Frett
Future Medicinal Chemistry|February 14, 2022
Targeting TGF-β: triumphs and challengesBaku Acharya, Sayem Miah, Brendan Frett
Expert Opinion on Therapeutic Patents|June 12, 2025
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)Daniel Armstrong, Maha Hanafi, Brendan Frett
Organic Letters|May 24, 2014
Efficient access to 2,3-diarylimidazo[1,2-a]pyridines via a one-pot, ligand-free, palladium-catalyzed three-component reaction under microwave irradiationYuanxiang Wang, Brendan Frett, Hong-yu Li
Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry|February 5, 2016
Selective Reduction of Halogenated Nitroarenes with Hydrazine Hydrate in the Presence of Pd/CFang Li, Brendan Frett, Hong-Yu Li
Chemmedchem|August 14, 2013
Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?Brendan Frett, Yuanxiang Wang, Hong-Yu Li
Organic & Biomolecular Chemistry|January 23, 2015
Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral mediaYuanxiang Wang, Brendan Frett, Nick McConnell, et al.
Acta Crystallographica. Section E, Structure Reports Online|June 25, 2013
(Z)-N-tert-Butyl-2-(4-meth-oxy-anilino)-N'-(4-meth-oxy-phen-yl)-2-phenyl-acetimidamideSue A Roberts, Biswajit Saha, Brendan Frett, et al.
Journal of Medicinal Chemistry|April 10, 2013
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulatorsYuanxiang Wang, Christine E Kaiser, Brendan Frett, et al.
RSC Medicinal Chemistry|August 4, 2022
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigmsBaku Acharya, Debasmita Saha, Daniel Armstrong, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Expert Opinion on Therapeutic Patents|October 5, 2022
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present)Baku Acharya, Brendan Frett
Future Medicinal Chemistry|February 14, 2022
Targeting TGF-β: triumphs and challengesBaku Acharya, Sayem Miah, Brendan Frett
Expert Opinion on Therapeutic Patents|June 12, 2025
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)Daniel Armstrong, Maha Hanafi, Brendan Frett
Organic Letters|May 24, 2014
Efficient access to 2,3-diarylimidazo[1,2-a]pyridines via a one-pot, ligand-free, palladium-catalyzed three-component reaction under microwave irradiationYuanxiang Wang, Brendan Frett, Hong-yu Li
Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry|February 5, 2016
Selective Reduction of Halogenated Nitroarenes with Hydrazine Hydrate in the Presence of Pd/CFang Li, Brendan Frett, Hong-Yu Li
Chemmedchem|August 14, 2013
Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?Brendan Frett, Yuanxiang Wang, Hong-Yu Li
Organic & Biomolecular Chemistry|January 23, 2015
Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral mediaYuanxiang Wang, Brendan Frett, Nick McConnell, et al.
Acta Crystallographica. Section E, Structure Reports Online|June 25, 2013
(Z)-N-tert-Butyl-2-(4-meth-oxy-anilino)-N'-(4-meth-oxy-phen-yl)-2-phenyl-acetimidamideSue A Roberts, Biswajit Saha, Brendan Frett, et al.
Journal of Medicinal Chemistry|April 10, 2013
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulatorsYuanxiang Wang, Christine E Kaiser, Brendan Frett, et al.
RSC Medicinal Chemistry|August 4, 2022
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigmsBaku Acharya, Debasmita Saha, Daniel Armstrong, et al.
Pageof 6